Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Atypical myelitis in patients with multiple sclerosis: characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders
Multiple Sclerosis
P13 - Poster Session 13 (5:30 PM-6:30 PM)
9-012

To characterize a cohort of MS patients with atypical myelitis.

Atypical myelitis in multiple sclerosis (MS) is characterised by extensive myelitis in the longitudinal (longitudinally extensive transverse myelitis) or axial plane (transverse myelitis).
Atypical myelitis were extracted from the French and Luxembourg MS databases and compared to two cohorts of MS patients with typical myelitis and NMOSD patients with myelitis.
We enrolled 28 MS patients with atypical myelitis, 68 MS patients with typical myelitis and 119 NMOSD patients with a first episode of myelitis. MS patients with atypical myelitis were characterized by a mean age of 34.0 (±10.7) years and 64.3% of women. In 82.1% of patients, atypical myelitis was the first episode of MS. After a mean follow-up of 39.6 (±30.4) months, 28% of patients had converted to a progressive form. Mean EDSS scores at nadir and 3-6 months after onset were 4.1±2.1 and 3.3±2, respectively. Differences between groups revealed a predominance of cervicodorsal myelitis and a higher level of disability in NMOSD patients. Disability in MS patients with atypical myelitis was more severe than in the MS patients with typical myelitis. 
Atypical myelitis is often the first presentation of MS and is associated with poor recovery. 
Authors/Disclosures
Kevin Bigaut
PRESENTER 		Kevin Bigaut has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Kevin Bigaut has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche.
Mikael Cohen (Hopital Pasteur) Mikael Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Roche, Merck, Ad scientiam, Novartis, Alexion, BMS.
Jonathan Ciron, MD (CHU Toulouse) Jonathan Ciron, MD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Jonathan Ciron, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Jonathan Ciron, MD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Jonathan Ciron, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS - Celgene. Jonathan Ciron, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion.
Bertrand Bourre Bertrand Bourre has nothing to disclose.
No disclosure on file
Pierre Labauge, MD Dr. Labauge has nothing to disclose.
Nicolas Collongues, MD (Hopital Civil) Nicolas Collongues, MD has nothing to disclose.